Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 2,597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Otitis Media
Interventions: telithromycin (HMR3647); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 59 Months
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Acute Bacterial Sinusitis
Interventions: cefdinir (Omnicef), levofloxacin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Columbiana, Alabama • Eclectic, Alabama + 16 more

Conditions: Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Interventions: In-person cardiac rehabilitation, Telehealth cardiac rehabilitation; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Bacterial Infections
Interventions: ceftaroline, vancomycin plus aztreonam, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 17
States / cities: Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Conditions: Mental Disorder
Interventions: Care Management; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Type 2 Diabetes
Interventions: Insulin Glargine, Metformin, Prandial insulin, Exenatide; Drug
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more

Conditions: Calcinosis Cutis
Interventions: Sodium Thiosulfate, Saline Solution; Drug · Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Type 2 Diabetes
Interventions: Capillary HbA1c collection; Procedure
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • Denver, Colorado • Honolulu, Hawaii + 2 more

Conditions: Breast Neoplasms
Interventions: Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: West Hollywood, California • Boston, Massachusetts

Conditions: Obesity
Interventions: Dietician / Health Coach, Health Coach / Dietician; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Renal Stone, Ureteral Stone
Interventions: Silicone (Coloplast Imajin Hydro) ureteral stent, Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer); Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Ann Arbor, Michigan • Brighton, Michigan • Chelsea, Michigan + 7 more

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sylmar, California • Royal Oak, Michigan • Lima, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: SECONDARY dressing gauze and tape, debridement, irrigation, Dermagraft, Oasis; Device · Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Osteoporosis, Postmenopausal
Interventions: Denosumab; Biological
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas

Conditions: Urinary Tract Infections
Interventions: Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: La Mesa, California • San Diego, California • Pensacola, Florida + 2 more

Conditions: Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions: olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: West Hollywood, California • Philadelphia, Pennsylvania

Conditions: Neoplasms, Febrile Neutropenia
Interventions: CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tonsillitis, Pharyngitis
Interventions: Telithromycin (HMR3647), Penicillin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 13 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Low Back Pain
Interventions: Naproxen, Placebo, Diazepam; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 69 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neonatal Abstinence Syndrome
Interventions: Telemedicine, Group Care; Behavioral
Lead sponsor: Wendy F Hansen; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 11
States / cities: Ashland, Kentucky • Bowling Green, Kentucky • Corbin, Kentucky + 7 more

Conditions: Renal Disease
Interventions: Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus; Drug
Lead sponsor: NephroNet, Inc.; Other
Eligibility: 65 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Lawrenceville, Georgia

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 7,466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma

Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Engaging Patients With Mental Disorders From the ED in Outpatient Care

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis

The GRADE Capillary Blood Collection Pilot Study

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

EHR Embedded Comparative Effectiveness Studies--WWC

Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES)

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

TELI TON - Telithromycin in Tonsillitis

Diazepam Use With Standard Management for Acute Low Back Pain

The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice